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OBJECTIVE: We conducted a multi-national pharmaco-
economic analysis of oral therapies in the management of
major depressive disorder (MDD) in 10 countries located
in Europe, Latin America, and North America. The study
was performed by an independent group of researchers
under an unrestricted grant from Wyeth-Ayerst Labora-
tories. Data used to populate country-specific decision
analytic models were derived from an international meta-
analysis, a Delphi panel (conducted in each country to as-
certain local practice patterns), and a financial analysis to
valuate resources consumed with local currencies. Health
care system information was collected in order to model
pharmacoeconomic and net economic endpoints.
METHODS: We performed a patient-level pharmacoeco-
nomic evaluation of MDD using a decision analytic ap-
proach. We then applied the pharmacoeconomic results
at the policy level to calculate the net economic (budget-
ary) impact of shifting medical prescribing practice to the
most cost-effective therapy. The perspective for the analy-
sis was that of the public payor (i.e., government) for all
countries studied except for the US, where the managed
care perspective was evaluated.
RESULTS: When weighted by population size, the 10-
country average expected cost of treatment of major de-
pression with venlafaxine is US$3,750 per patient, com-
pared to US$4,460 for SSRIs and US$4,630 for TCAs.
Thus, treatment of major depression with venlafaxine pre-
sents substantial per-patient cost savings compared to SS-
RIs (US$710) and TCAs (US$880). Direct costs evaluated
include the cost of pharmacuetical agents, physician ser-
vices, laboratory services, and hospitalization. The ex-
pected cost savings attributible to venlafaxine are a func-
tion of a reduced requirement for health care services.
CONCLUSIONS: The net economic impact of a 1% shift
in venlafaxine utilization in the 10 countries studied trans-
lates to a savings of US$14.24 million in total direct cost to
society and a US$7.74 million in direct cost to the primary
payers. The results withstand comprehensive sensitivity
analysis.
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Abstracts
PURPOSE: The objective of this study was to assess utili-
zation patterns of different antidepressants in patients
served by a medical group using pharmacy claims data
from two third-party insurers.
METHODS: Patients must have been 18 to 65 years of
age, receiving a new prescription of anti-depressant be-
tween the period of 1994-1996. Definition of adequate
dose and duration of anti-depressant therapy were based
on 1993 AHCPR guidelines. Switching of therapy was
defined when the patient discontinued the original antide-
pressant after addition of a second antidepressant,
whereas augmentation was defined when the patient con-
tinued to purchase the original antidepressant at least
once after addition of the second antidepressant. A dos-
age was considered titrated if the average daily dose for
any of the first three prescriptions was different from any
of the other two. All the analyses were performed based
on the initial therapy.
RESULTS: The patient sample included 177 (18.8%) pa-
tients who received fluoxetine as initial therapy, 98
(10.4%) sertraline, 175 (18.6%) paroxetine, 373 (39.6%)
tricyclic antidepressants (TCAs), and 119 (12.3%) other
antidepressants. The treatment completion rate was: flu-
oxetine 18.6%, sertraline 14.3%, paroxetine 6.9%,
TCAs 3%, and other antidepressants 7.6%. All of the
pairwise comparisons vs. fluoxetine were statistically sig-
nificant, except for the one with sertraline. The switch
rate ranged from 5.6% for, TCAs to 13.7% for paroxet-
ine. No difference in augmentation rate was found
among SSRIs (fluoxetine, 6.8%; sertraline, 4.1 %; parox-
etine, 5.7%), while the augmentation rate for fluoxetine
was statistically significantly higher than TCAs (6.8% vs.
1.9%). The titration rate was 20.3% for fluoxetine,
28.1 % for sertraline, 21.9% for paroxetine, 40.2% for
TCAs, and 33.3% for other antidepressants (significant
difference between TCAs and fluoxetine).
CONCLUSIONS: Our data have demonstrated that there
were significant differences in utilization patterns among
antidepressants. Much more attention must be paid to
ensuring that newly treated patients achieve treatment
completion.
